Immunotherapy of rat glioma without accumulation of CD4+CD25+FOXP3+ regulatory T cells

Neural Regeneration Research

Volumn 7, Issue 19, 2012, Pages 1498-1506

  Feng, Enshan ^a   Gao, Haili ^b   Su, Wei ^b   Yu, Chunjiang ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Adoptive T cell; Combined immunotherapy; Dendritic cell; Glioma

Indexed keywords

TRANSCRIPTION FACTOR FOXP3;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD25+ T LYMPHOCYTE; CD4+ CD25+ FOXP3+ REGULATORY T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; FOXP3+ T LYMPHOCYTE; GLIOBLASTOMA; IMMUNE RESPONSE; IMMUNOCYTOCHEMISTRY; IMMUNOTHERAPY; LYMPHOCYTIC INFILTRATION; NONHUMAN; RAT; REGULATORY T LYMPHOCYTE; SURVIVAL RATE; TUMOR VOLUME; VACCINATION;

EID: 84864809197     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.3969/j.issn.1673-5374.2012.19.009     Document Type: Article

References (48)

1. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109(1):93-108.
2. Behin A, Hoang-Xuan K, Carpentier AF, et al. Primary brain tumours in adults. Lancet. 2003;361(9354):323-331.
3. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-466.
4. De Vleeschouwer S, Fieuws S, Rutkowski S, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res. 2008;14(10):3098-3104.
5. Van Gool S, Maes W, Ardon H, et al. Dendritic cell therapy of high-grade gliomas. Brain Pathol. 2009;19(4):694-712.
6. Zhou G, Drake CG, Levitsky HI. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood. 2006;107(2):628-636.
7. Melief CJ. Cancer immunotherapy by dendritic cells. Immunity. 2008;29(3):372-383.
8. Zitvogel L, Apetoh L, Ghiringhelli F, et al. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008; 8(1):59-73.
9. Jiang XB, Lu XL, Hu P, et al. Improved therapeutic efficacy using vaccination with glioma lysate-pulsed dendritic cells combined with IP-10 in murine glioma. Vaccine. 2009; 27(44):6210-6216.
10. + regulatory T cells. Nat Immunol. 2003;4(4):330-336.
11. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609):1057-1061.
12. + T regulatory cells. Nat Immunol. 2003;4(4):337-342.
13. Wildin RS, Ramsdell F, Peake J, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet. 2001;27(1):18-20.
14. Burchill MA, Yang J, Vang KB, et al. Linked T cell receptor and cytokine signaling govern the development of the regulatory T cell repertoire. Immunity. 2008;28(1):112-121.
15. Lio CW, Hsieh CS. A two-step process for thymic regulatory T cell development. Immunity. 2008;28(1): 100-111.
16. Fecci PE, Mitchell DA, Whitesides JF, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 2006;66(6): 3294-3302.
17. Sonabend AM, Rolle CE, Lesniak MS. The role of regulatory T cells in malignant glioma. Anticancer Res. 2008;28(2B):1143-1150.
18. Zhu X, Lu C, Xiao B, et al. An experimental study of dendritic cells-mediated immunotherapy against intracranial gliomas in rats. J Neurooncol. 2005;74(1): 9-17.
19. Calzascia T, Masson F, Di Berardino-Besson W, et al. Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity. 2005;22(2):175-184.
20. + T cells and dendritic cells in vivo. J Exp Med. 2006;203(3):505-511.
21. Tang Q, Adams JY, Tooley AJ, et al. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol. 2006;7(1):83-92.
22. Yu P, Lee Y, Liu W, et al. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med. 2005;201(5): 779-791.
23. Piersma SJ, Welters MJ, van der Burg SH. Tumor-specific regulatory T cells in cancer patients. Hum Immunol. 2008; 69(4-5):241-249.
24. Gallimore A, Godkin A. Regulatory T cells and tumour immunity-observations in mice and men. Immunology. 2008;123(2):157-163.
25. Okada H, Kohanbash G, Zhu X, et al. Immunotherapeutic approaches for glioma. Crit Rev Immunol. 2009;29(1): 1-42.
26. Chang AE, Redman BG, Whitfield JR, et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res. 2002;8(4):1021-1032.
27. Papewalis C, Fassnacht M, Willenberg HS, et al. Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma. Clin Endocrinol (Oxf). 2006; 65(2):215-222.
28. George TC, Bilsborough J, Viney JL, et al. High antigen dose and activated dendritic cells enable Th cells to escape regulatory T cell-mediated suppression in vitro. Eur J Immunol. 2003;33(2):502-511.
29. + T cells. J Immunol. 2008; 180(5):3122-3131.
30. + Treg. Eur J Immunol. 2009;39(5):1323-1333.
31. Hussain SF, Yang D, Suki D, et al. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol. 2006;8(3): 261-279.
32. + T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J Neurooncol. 2007; 83(2):145-152.
33. Ghiringhelli F, Ménard C, Martin F, et al. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev. 2006; 214:229-238.
34. + regulatory T cells. J Immunol. 2005;175(7):4180-4183.
35. Bui JD, Uppaluri R, Hsieh CS, et al. Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Cancer Res. 2006;66(14):7301-7309.
36. Nestle FO, Banchereau J, Hart D. Dendritic cells: On the move from bench to bedside. Nat Med. 2001;7(7): 761-765.
37. Tran DQ, Shevach EM. Therapeutic potential of FOXP3(+) regulatory T cells and their interactions with dendritic cells. Hum Immunol. 2009;70(5):294-299.
38. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer. 2003;3(9):666-675.
39. Rozková D, Tiserová H, Fucíková J, et al. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer. Clin Immunol. 2009;131(1):1-10.
40. Ruter J, Barnett BG, Kryczek I, et al. Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. Front Biosci. 2009; 14:1761-1770.
41. Jordan JT, Sun W, Hussain SF, et al. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother. 2008;57(1): 123-131.
42. Curiel TJ. Regulatory T cells and treatment of cancer. Curr Opin Immunol. 2008;20(2):241-246.
43. Taniguchi T, Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell. 1993;73(1):5-8.
44. + T cells. Cell Mol Immunol. 2006;3(3): 189-195.
45. Curtin JF, Candolfi M, Fakhouri TM, et al. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS One. 2008;3(4):e1983.
46. +T cells controlling distinct organ-specific autoimmune diseases. Proc Natl Acad Sci U S A. 2003; 100(26):15806-15811.
47. The Ministry of Science and Technology of the People's Republic of China. Guidance Suggestions for the Care and Use of Laboratory Animals. 2006-09-30.
48. Chen-Woan M, Delaney CP, Fournier V, et al. In vitro characterization of rat bone marrow-derived dendritic cells and their precursors. J Leukoc Biol. 1996;59(2):196-207.